Aromatic L-amino acid decarboxylase inhibitor

From Wikipedia, the free encyclopedia
  (Redirected from Dopa decarboxylase inhibitor)
Jump to: navigation, search
Peripheral inhibitors of DOPA decarboxylase (AADC) block one of two ways levodopa can be inactivated before it reaches the central nervous system and is activated to dopamine. (Dopamine in the periphery only causes side effects, no antiparkinson effect.) COMT inhibitors block the second way.[1]

An aromatic L-amino acid decarboxylase inhibitor (synonyms: DOPA decarboxylase inhibitor, DDCI and AAADI) is a drug which inhibits the synthesis of dopamine by the enzyme aromatic L-amino acid decarboxylase (AADC, AAAD, or DOPA decarboxylase).

Indications[edit]

Peripheral DDCIs incapable of crossing the protective blood-brain-barrier (BBB) are used in augmentation of L-DOPA (levodopa) in the treatment of Parkinson's disease (PD) to block the peripheral conversion of L-DOPA into dopamine for the purpose of reducing adverse side effects.[2] Combined l-dopa and DDCI therapy does not inherently decrease peripheral cardiovascular side effects of l-dopa administration; however, combined therapy potentiates the central effects of l-dopa by decreasing the dose-dependency 4-5 fold, therein allowing for effective Parkinson's Disease treatment without cardiovascular risk associated with high peripheral dopamine.[3][4]

List of DDCIs[edit]

  • Benserazide (Madopar, Prolopa, Modopar, Madopark, Neodopasol, EC-Doparyl, etc.)
  • Carbidopa (Lodosyn, Sinemet, Parcopa, Atamet, Stalevo, etc.)
  • Methyldopa (Aldomet, Aldoril, Dopamet, Dopegyt, etc.)
  • DFMD
  • 3',4',5,7-Tetrahydroxy-8-methoxyisoflavone [58262-89-8]

References[edit]

  1. ^ Mutschler, Ernst; Schäfer-Korting, Monika (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. p. 313–316. ISBN 3-8047-1763-2. 
  2. ^ "Editorial: Dopa decarboxylase inhibitors". British Medical Journal. 4 (5939): 250–1. November 1974. doi:10.1136/bmj.4.5939.250. PMC 1612227Freely accessible. PMID 4425849. 
  3. ^ Cotzias, G. C., Papavasiliou, P. S., and Gellene, R., New England Journalof Medicine, 1969, 280, 337.
  4. ^ Yahr, M. D., in Advances in Neurology, ed. M. D. Yahr, p. vi, vol. 2. New York, Raven Press, 1973.